| 1 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | 1.0 | 1 | Citations (PDF) |
| 2 | Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia | 2.7 | 5 | Citations (PDF) |
| 3 | A man’s best friend is his PETBlood, 2023, 141, 3010-3012 | 3.6 | 1 | Citations (PDF) |
| 4 | Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial | 2.0 | 6 | Citations (PDF) |
| 5 | Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study | 4.5 | 31 | Citations (PDF) |
| 6 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyBlood, 2021, 137, 2817-2826 | 3.6 | 46 | Citations (PDF) |
| 7 | Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic | 2.4 | 20 | Citations (PDF) |
| 8 | Diffuse large B-cell lymphoma: new targets and novel therapies | 4.1 | 79 | Citations (PDF) |
| 9 | Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma | 12.3 | 157 | Citations (PDF) |
| 10 | Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma | 2.4 | 4 | Citations (PDF) |
| 11 | Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy | 2.3 | 16 | Citations (PDF) |
| 12 | Current Role of Functional Imaging in the Management of Lymphoma | 2.8 | 20 | Citations (PDF) |
| 13 | Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study | 7.4 | 161 | Citations (PDF) |
| 14 | Copanlisib in the treatment of non-Hodgkin lymphoma | 1.7 | 15 | Citations (PDF) |
| 15 | Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical TrialBlood, 2020, 135, 2224-2234 | 3.6 | 92 | Citations (PDF) |
| 16 | Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy | 4.5 | 111 | Citations (PDF) |
| 17 | Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 | 5.2 | 19 | Citations (PDF) |
| 18 | Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature | 0.1 | 2 | Citations (PDF) |
| 19 | Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma | 1.6 | 6 | Citations (PDF) |
| 20 | Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma | 1.0 | 15 | Citations (PDF) |
| 21 | Targeting Biology in Non-Hodgkin Lymphoma | 1.5 | 3 | Citations (PDF) |
| 22 | Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance) | 2.7 | 11 | Citations (PDF) |
| 23 | Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice | 4.5 | 86 | Citations (PDF) |
| 24 | Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) | 7.4 | 237 | Citations (PDF) |
| 25 | Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 | 12.3 | 401 | Citations (PDF) |
| 26 | Phase 2 multicentre study of single‐agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance) | 1.6 | 12 | Citations (PDF) |
| 27 | A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL | 3.7 | 26 | Citations (PDF) |
| 28 | Introduction by the Guest Editor | 1.0 | 0 | Citations (PDF) |
| 29 | Targeted Therapies in Chronic Lymphocytic Leukemia | 1.0 | 1 | Citations (PDF) |
| 30 | The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials | 2.0 | 42 | Citations (PDF) |
| 31 | Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?Blood, 2019, 133, 121-129 | 3.6 | 21 | Citations (PDF) |
| 32 | Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas | 1.0 | 41 | Citations (PDF) |
| 33 | Descriptive analysis of genetic aberrations and cell of origin in Richter transformation | 1.0 | 5 | Citations (PDF) |
| 34 | MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial | 3.6 | 33 | Citations (PDF) |
| 35 | Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611) | 1.3 | 6 | Citations (PDF) |
| 36 | PET/CT in Lymphoma: Current Overview and Future Directions | 3.4 | 70 | Citations (PDF) |
| 37 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial | 14.5 | 368 | Citations (PDF) |
| 38 | A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL | 3.7 | 21 | Citations (PDF) |
| 39 | CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETBlood, 2018, 132, 1013-1021 | 3.6 | 110 | Citations (PDF) |
| 40 | Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma | 1.0 | 3 | Citations (PDF) |
| 41 | Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial | 5.2 | 67 | Citations (PDF) |
| 42 | Determining the sequence of novel therapies in the treatment of relapsed Hodgkin’s lymphoma | 1.5 | 1 | Citations (PDF) |
| 43 | Recommendations for Clinical Trial Development in Follicular Lymphoma | 3.4 | 23 | Citations (PDF) |
| 44 | Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma | 1.6 | 31 | Citations (PDF) |
| 45 | Pros and cons of rituximab maintenance in follicular lymphoma | 6.0 | 9 | Citations (PDF) |
| 46 | Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials | 7.4 | 78 | Citations (PDF) |
| 47 | RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106 | 1.6 | 47 | Citations (PDF) |
| 48 | Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents | 2.4 | 70 | Citations (PDF) |
| 49 | Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies | 1.0 | 14 | Citations (PDF) |
| 50 | Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | 4.5 | 91 | Citations (PDF) |
| 51 | Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceBlood, 2016, 128, 2199-2205 | 3.6 | 186 | Citations (PDF) |
| 52 | Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Blood, 2016, 128, 2510-2516 | 3.6 | 59 | Citations (PDF) |
| 53 | Speed bumps on the road to a chemotherapy-free world for lymphoma patientsBlood, 2016, 128, 325-330 | 3.6 | 17 | Citations (PDF) |
| 54 | Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBlood, 2016, 128, 2489-2496 | 3.6 | 497 | Citations (PDF) |
| 55 | PI3K signaling pathway in normal B cells and indolent B-cell malignancies | 2.9 | 34 | Citations (PDF) |
| 56 | Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial | 14.5 | 344 | Citations (PDF) |
| 57 | The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia | 1.4 | 28 | Citations (PDF) |
| 58 | 18F‐FDG PET‐CT and trephine biopsy assessment of bone marrow involvement in lymphoma | 1.6 | 36 | Citations (PDF) |
| 59 | Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone | 1.1 | 25 | Citations (PDF) |
| 60 | Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)Blood, 2016, 128, 2953-2953 | 3.6 | 4 | Citations (PDF) |
| 61 | Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell MalignanciesBlood, 2016, 128, 2961-2961 | 3.6 | 1 | Citations (PDF) |
| 62 | Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN StudyBlood, 2016, 128, 2980-2980 | 3.6 | 3 | Citations (PDF) |
| 63 | Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group TrialBlood, 2016, 128, 2992-2992 | 3.6 | 5 | Citations (PDF) |
| 64 | Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World PatientsBlood, 2016, 128, 3222-3222 | 3.6 | 16 | Citations (PDF) |
| 65 | Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-PatientsBlood, 2016, 128, 4400-4400 | 3.6 | 2 | Citations (PDF) |
| 66 | Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303Blood, 2016, 128, 469-469 | 3.6 | 80 | Citations (PDF) |
| 67 | Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611)Blood, 2016, 128, 536-536 | 3.6 | 2 | Citations (PDF) |
| 68 | Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN StudyBlood, 2016, 128, 615-615 | 3.6 | 22 | Citations (PDF) |
| 69 | Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016Blood, 2016, 128, 616-616 | 3.6 | 3 | Citations (PDF) |
| 70 | Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or IdelalisibBlood, 2016, 128, 637-637 | 3.6 | 49 | Citations (PDF) |
| 71 | Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era | 1.6 | 74 | Citations (PDF) |
| 72 | Rethinking Clinical Response and Outcome Assessment in a Biologic Age | 2.8 | 4 | Citations (PDF) |
| 73 | Advances in the treatment of follicular lymphoma | 2.1 | 0 | Citations (PDF) |
| 74 | A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas | 1.6 | 12 | Citations (PDF) |
| 75 | What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows? | 1.5 | 10 | Citations (PDF) |
| 76 | Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma | 1.0 | 30 | Citations (PDF) |
| 77 | Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501) | 1.0 | 36 | Citations (PDF) |
| 78 | Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin LymphomaBlood, 2015, 126, 1532-1532 | 3.6 | 5 | Citations (PDF) |
| 79 | Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)Blood, 2015, 126, 2741-2741 | 3.6 | 3 | Citations (PDF) |
| 80 | Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)Blood, 2015, 126, 334-334 | 3.6 | 2 | Citations (PDF) |
| 81 | Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403Blood, 2015, 126, 337-337 | 3.6 | 23 | Citations (PDF) |
| 82 | Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin LymphomaBlood, 2015, 126, 3978-3978 | 3.6 | 17 | Citations (PDF) |
| 83 | Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)Blood, 2015, 126, 471-471 | 3.6 | 15 | Citations (PDF) |
| 84 | Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell LymphomaBlood, 2015, 126, 518-518 | 3.6 | 5 | Citations (PDF) |
| 85 | Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center StudyBlood, 2015, 126, 719-719 | 3.6 | 10 | Citations (PDF) |
| 86 | Lenalidomide following fludarabine and rituximab in previously untreated CLL | 0.0 | 0 | Citations (PDF) |
| 87 | Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin LymphomaBlood, 2015, 126, 3961-3961 | 3.6 | 0 | Citations (PDF) |
| 88 | Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with IdelalisibBlood, 2015, 126, 2952-2952 | 3.6 | 0 | Citations (PDF) |
| 89 | Bendamustine: role and evidence in lymphoma therapy, an overview | 1.0 | 25 | Citations (PDF) |
| 90 | A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors | 15.4 | 92 | Citations (PDF) |
| 91 | Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia | 19.4 | 1,651 | Citations (PDF) |
| 92 | Current role of FDG PET/CT in lymphoma | 3.7 | 69 | Citations (PDF) |
| 93 | Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 | 1.6 | 88 | Citations (PDF) |
| 94 | How we manage follicular lymphoma | 3.6 | 86 | Citations (PDF) |
| 95 | Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification | 12.3 | 5,334 | Citations (PDF) |
| 96 | CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells | 3.1 | 51 | Citations (PDF) |
| 97 | A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics | 1.3 | 24 | Citations (PDF) |
| 98 | Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group | 12.3 | 1,555 | Citations (PDF) |
| 99 | Which Hodgkin’s Patients in the Unites States Should Be Treated with BEACOPP? | 2.2 | 2 | Citations (PDF) |
| 100 | CLL and NHL: the end of chemotherapy?Blood, 2014, 123, 3368-3370 | 3.6 | 12 | Citations (PDF) |
| 101 | Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202Blood, 2014, 124, 3091-3091 | 3.6 | 28 | Citations (PDF) |
| 102 | Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic FactorsBlood, 2014, 124, 330-330 | 3.6 | 63 | Citations (PDF) |
| 103 | Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin LymphomaBlood, 2014, 124, 4457-4457 | 3.6 | 27 | Citations (PDF) |
| 104 | The Optimal Management of Follicular Lymphoma: An Evolving FieldDrugs, 2013, 73, 1395-1403 | 8.7 | 6 | Citations (PDF) |
| 105 | The current status and future impact of targeted therapies in non-Hodgkin lymphoma | 1.5 | 19 | Citations (PDF) |
| 106 | The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) | 1.0 | 28 | Citations (PDF) |
| 107 | PTCL Therapies | 0.4 | 3 | Citations (PDF) |
| 108 | State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response” | 1.7 | 33 | Citations (PDF) |
| 109 | A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 | 2.7 | 54 | Citations (PDF) |
| 110 | The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study | 1.0 | 25 | Citations (PDF) |
| 111 | A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab | 4.5 | 38 | Citations (PDF) |
| 112 | Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell MalignanciesBlood, 2013, 122, 1810-1810 | 3.6 | 15 | Citations (PDF) |
| 113 | The Utility Of 18f-FDG PET/CT In Assessing Bone Marrow Involvement In LymphomaBlood, 2013, 122, 2981-2981 | 3.6 | 2 | Citations (PDF) |
| 114 | Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)Blood, 2013, 122, 3002-3002 | 3.6 | 2 | Citations (PDF) |
| 115 | The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup ExperienceBlood, 2013, 122, 3060-3060 | 3.6 | 5 | Citations (PDF) |
| 116 | Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496Blood, 2013, 122, 4277-4277 | 3.6 | 3 | Citations (PDF) |
| 117 | Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)Blood, 2013, 122, 4399-4399 | 3.6 | 10 | Citations (PDF) |
| 118 | Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lymphome d’AdultesBlood, 2013, 122, 3045-3045 | 3.6 | 2 | Citations (PDF) |
| 119 | Management of Chronic Lymphocytic Leukaemia | 2.3 | 17 | Citations (PDF) |
| 120 | Oral FludarabineDrugs, 2012, 63, 2324-2325 | 8.7 | 0 | Citations (PDF) |
| 121 | The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma | 4.2 | 7 | Citations (PDF) |
| 122 | Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness | 8.1 | 63 | Citations (PDF) |
| 123 | Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? | 1.0 | 54 | Citations (PDF) |
| 124 | Bortezomib: A Proteasome Inhibitor with An Evolving Role in Select Subtypes of B-Cell Non-Hodgkin’s Lymphoma | 1.7 | 6 | Citations (PDF) |
| 125 | Brentuximab vedotin ushers in a new era in treating lymphomas | 0.0 | 0 | Citations (PDF) |
| 126 | A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma | 2.7 | 105 | Citations (PDF) |
| 127 | Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory LymphomaBlood, 2012, 120, 3646-3646 | 3.6 | 3 | Citations (PDF) |
| 128 | MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 StudyBlood, 2012, 120, 3677-3677 | 3.6 | 5 | Citations (PDF) |
| 129 | Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell TransplantBlood, 2012, 120, 3701-3701 | 3.6 | 7 | Citations (PDF) |
| 130 | A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | 3.6 | 7 | Citations (PDF) |
| 131 | Lenalidomide Following Rituximab and Fludarabine in Untreated CLLBlood, 2012, 120, 3924-3924 | 3.6 | 0 | Citations (PDF) |
| 132 | Cell of Origin in Richter's Transformation of CLLBlood, 2012, 120, 4574-4574 | 3.6 | 2 | Citations (PDF) |
| 133 | Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance RituximabBlood, 2012, 120, 3705-3705 | 3.6 | 0 | Citations (PDF) |
| 134 | BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)Blood, 2012, 120, 301-301 | 3.6 | 1 | Citations (PDF) |
| 135 | Role of Functional Imaging in the Management of Lymphoma | 12.3 | 273 | Citations (PDF) |
| 136 | New agents in follicular lymphoma | 1.6 | 10 | Citations (PDF) |
| 137 | Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETBlood, 2011, 117, 5314-5320 | 3.6 | 57 | Citations (PDF) |
| 138 | Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma | 2.7 | 231 | Citations (PDF) |
| 139 | Author reply: Rituximab maintenance for follicular lymphoma | 53.1 | 0 | Citations (PDF) |
| 140 | Syk [sic] of the same old chemotherapy?Blood, 2010, 115, 2561-2562 | 3.6 | 2 | Citations (PDF) |
| 141 | Targeted treatment and new agents in follicular lymphoma | 0.9 | 7 | Citations (PDF) |
| 142 | Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel | 1.0 | 86 | Citations (PDF) |
| 143 | The Sarcoid-Lymphoma Syndrome | 1.0 | 35 | Citations (PDF) |
| 144 | Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma | 1.0 | 52 | Citations (PDF) |
| 145 | Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism | 8.1 | 56 | Citations (PDF) |
| 146 | Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma | 1.5 | 9 | Citations (PDF) |
| 147 | Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies | 12.3 | 159 | Citations (PDF) |
| 148 | Monoclonal antibody therapy of chronic lymphocytic leukaemia | 1.6 | 16 | Citations (PDF) |
| 149 | Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)Blood, 2010, 116, 427-427 | 3.6 | 10 | Citations (PDF) |
| 150 | R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793Blood, 2010, 116, 589-589 | 3.6 | 8 | Citations (PDF) |
| 151 | Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202Blood, 2010, 116, 763-763 | 3.6 | 5 | Citations (PDF) |
| 152 | Bendamustine: Rebirth of an Old Drug | 12.3 | 251 | Citations (PDF) |
| 153 | Novel therapies for peripheral T-cell non-Hodgkinʼs lymphomas | 1.4 | 20 | Citations (PDF) |
| 154 | Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaBlood, 2009, 113, 299-305 | 3.6 | 265 | Citations (PDF) |
| 155 | Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis.Blood, 2009, 114, 2681-2681 | 3.6 | 5 | Citations (PDF) |
| 156 | Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.Blood, 2009, 114, 3441-3441 | 3.6 | 6 | Citations (PDF) |
| 157 | A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.Blood, 2009, 114, 3742-3742 | 3.6 | 8 | Citations (PDF) |
| 158 | Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma | 19.4 | 433 | Citations (PDF) |
| 159 | Thalidomide has limited single‐agent activity in relapsed or refractory indolent non‐Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B | 1.6 | 28 | Citations (PDF) |
| 160 | Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study | 1.0 | 106 | Citations (PDF) |
| 161 | Staging and Evaluation of the Patient with Lymphoma | 1.5 | 26 | Citations (PDF) |
| 162 | Bendamustine: a potential new option for patients with refractory hematologic malignancies | 0.0 | 0 | Citations (PDF) |
| 163 | Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma | 12.3 | 343 | Citations (PDF) |
| 164 | Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study | 12.3 | 281 | Citations (PDF) |
| 165 | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008, 111, 5446-5456 | 3.6 | 3,016 | Citations (PDF) |
| 166 | New Staging and Response Criteria for Non-Hodgkin Lymphoma and Hodgkin Lymphoma | 1.1 | 30 | Citations (PDF) |
| 167 | Lenalidomide for the Treatment of B-Cell Malignancies | 12.3 | 174 | Citations (PDF) |
| 168 | New response criteria for lymphomas in clinical trials | 8.1 | 26 | Citations (PDF) |
| 169 | Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma | 8.1 | 175 | Citations (PDF) |
| 170 | Implementing an Expressive Writing Study in a Cancer Clinic | 2.4 | 44 | Citations (PDF) |
| 171 | Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma | 1.0 | 18 | Citations (PDF) |
| 172 | PET Scans for Lymphoma (8/25/08 issue) | 0.1 | 0 | Citations (PDF) |
| 173 | FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].Blood, 2008, 112, 1003-1003 | 3.6 | 6 | Citations (PDF) |
| 174 | Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s LymphomaBlood, 2008, 112, 233-233 | 3.6 | 6 | Citations (PDF) |
| 175 | The role of FDG-PET scans in patients with lymphomaBlood, 2007, 110, 3507-3516 | 3.6 | 297 | Citations (PDF) |
| 176 | Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 | 1.0 | 40 | Citations (PDF) |
| 177 | Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 | 1.0 | 64 | Citations (PDF) |
| 178 | Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 | 8.1 | 257 | Citations (PDF) |
| 179 | The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials | 1.5 | 120 | Citations (PDF) |
| 180 | Clinical Management of T-Cell Malignancies: Current Perspectives, Key Issues, and Emerging Therapies | 2.9 | 11 | Citations (PDF) |
| 181 | Is BEACOPP better than ABVD? | 2.2 | 11 | Citations (PDF) |
| 182 | Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.Blood, 2007, 110, 1351-1351 | 3.6 | 6 | Citations (PDF) |
| 183 | A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.Blood, 2007, 110, 892-892 | 3.6 | 6 | Citations (PDF) |
| 184 | Positron-Emission Tomography and Assessment of Cancer Therapy | 19.4 | 713 | Citations (PDF) |
| 185 | Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006, 108, 419-425 | 3.6 | 1,551 | Citations (PDF) |
| 186 | Monoclonal Antibody Therapy for B-Cell Malignancies | 2.9 | 44 | Citations (PDF) |
| 187 | Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906 | 1.0 | 9 | Citations (PDF) |
| 188 | Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography | 12.3 | 373 | Citations (PDF) |
| 189 | The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development | 4.5 | 222 | Citations (PDF) |
| 190 | What Is New in Lymphoma? | 353.4 | 37 | Citations (PDF) |
| 191 | Novel therapies for chronic lymphocytic leukemia | 3.9 | 29 | Citations (PDF) |
| 192 | Radioimmunotherapy of non-Hodgkin lymphomasBlood, 2003, 101, 391-398 | 3.6 | 167 | Citations (PDF) |
| 193 | Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia | 12.3 | 68 | Citations (PDF) |
| 194 | Rituximab: clinical development and future directions | 1.9 | 36 | Citations (PDF) |
| 195 | A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL) | 2.5 | 55 | Citations (PDF) |
| 196 | Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyBlood, 2002, 99, 2685-2693 | 3.6 | 325 | Citations (PDF) |
| 197 | Updated Metaanalysis Finds That Interferon-α Improves Progression-Free and Overall Survival in Low-Grade Non-Hodgkin's Lymphoma When Administered with Chemotherapy That Contains Anthracyclines or Mitoxantrone | 1.8 | 5 | Citations (PDF) |
| 198 | Pre- and post-treatment evaluation of non-Hodgkin's lymphoma | 1.6 | 12 | Citations (PDF) |
| 199 | Hematologic malignancies: New developments and future treatments | 2.9 | 4 | Citations (PDF) |
| 200 | Hematologic malignancies: New developments and future treatments | 2.9 | 63 | Citations (PDF) |
| 201 | Rational Approaches to Design of Therapeutics Targeting Molecular Markers | 1.8 | 19 | Citations (PDF) |
| 202 | New drug development in non-hodgkin lymphomas | 2.8 | 4 | Citations (PDF) |
| 203 | Emerging therapies and future directions in chronic lymphocytic leukaemia - chemotherapy | 0.1 | 4 | Citations (PDF) |
| 204 | Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH | 12.3 | 126 | Citations (PDF) |
| 205 | Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia | 19.4 | 958 | Citations (PDF) |
| 206 | Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias | 12.3 | 201 | Citations (PDF) |
| 207 | Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas | 12.3 | 3,297 | Citations (PDF) |
| 208 | Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma | 3.6 | 526 | Citations (PDF) |
| 209 | Ennui or not ennui, that is the question… | 8.1 | 1 | Citations (PDF) |
| 210 | Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia | 1.0 | 8 | Citations (PDF) |
| 211 | New modalities of therapy in chronic lymphocytic leukemia | 3.5 | 4 | Citations (PDF) |
| 212 | New Chemotherapeutic Agents for Non-Hodgkin’s Lymphomas | 1.5 | 5 | Citations (PDF) |
| 213 | Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: Experience of the non-Hodgkin's lymphoma pathologic classification project | 0.0 | 17 | Citations (PDF) |
| 214 | Pentostatin in Hairy Cell Leukemia: Treatment by the Special Exception Mechanism | 3.4 | 38 | Citations (PDF) |
| 215 | Autologous Bone Marrow Transplantation | 7.3 | 128 | Citations (PDF) |
| 216 | The Non-Hodgkin Lymphoma Pathologic Classification Project | 7.3 | 102 | Citations (PDF) |
| 217 | 2′-Deoxycoformycin (Pentostatin) for Lymphoid Malignancies | 7.3 | 102 | Citations (PDF) |
| 218 | Suramin Therapy in AIDS and Related Disorders | 15.8 | 72 | Citations (PDF) |
| 219 | Clinical Trials in Hairy Cell Leukemia | 7.3 | 37 | Citations (PDF) |
| 220 | Hodgkin's Disease, Alcohol, and Vena Caval Obstruction | 15.8 | 1 | Citations (PDF) |
| 221 | Title is missing! 0 | | 1 | Citations (PDF) |
| 222 | The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress | 3.6 | 0 | Citations (PDF) |
